Check US and UK donation rules, topical-finasteride differences, and what to tell the collection service before booking.
Finasteride and dutasteride can affect blood-donation eligibility even when you take them for hair loss and feel well. The American Red Cross lists a wait of one month after the last finasteride dose and six months after the last dutasteride dose. Do not stop prescribed treatment just to donate; ask your prescriber and the donation service how the rules apply to you. American Red Cross eligibility criteria.
The medication, route and donation service matter. Guidance checked October 6, 2026; the collecting service makes the eligibility decision.
For US Red Cross blood donation, the medication list names Propecia and Proscar (finasteride) and Avodart and Jalyn (dutasteride). Its one-month and six-month periods run from the last dose. A lower hair-loss dose is not an exemption stated in that list. If you still take the medicine, skipping the dose on donation day does not satisfy the waiting period.
UK guidance uses slightly different wording. The Joint Professional Advisory Committee's current whole blood and components entry says not to donate after systemic finasteride within the last four weeks, or systemic dutasteride within the last six months. That entry also considers the cause of hair loss, other treatments and specialist follow-up. Four weeks and one calendar month should not be silently substituted for each other. JPAC alopecia guidance, Edition 203 Release 81, August 11, 2026.
These are service-specific eligibility rules, not a calculation you should replace with an internet drug half-life estimate.
The concern is exposure of a pregnant transfusion recipient and a developing male fetus. The US Avodart label instructs people taking dutasteride to avoid blood donation during treatment and for at least six months after the last dose. This restriction is about protecting recipients; feeling healthy or having no side effects does not remove it. Avodart prescribing and patient information, sections 5.5 and 17.
A screening finger-prick or a previous successful donation is not a substitute for disclosing a current medication. Give staff the product name and the actual last-use date.
Ask about the exact formulation instead of assuming that “topical” means either automatically eligible or automatically excluded.
The current UK JPAC alopecia entry explicitly permits acceptance when the donor has only used topical finasteride, such as a spray, foam or lotion. The remaining eligibility requirements still apply. That UK provision is not permission to use the same rule at a different blood or plasma collection service.
The Red Cross public medication list does not provide the same explicit topical-finasteride exception. Contact its eligibility team before booking if you use a compounded spray or mixture. Report every active ingredient, whether you have also taken tablets, and when each route was last used.
Eligibility policy also should not be read as proof of zero absorption. FDA's topical-finasteride safety alert states that absorption through the skin into the bloodstream is expected. It also warns about inadvertent transfer to other people. Those safety findings and a donation service's eligibility rules answer different questions. FDA topical-finasteride alert.
Yes: disclose both medicines. For example, someone who stopped dutasteride recently and now takes finasteride should not assume that the shorter finasteride period clears the earlier dutasteride exposure. The service needs both last-dose dates before deciding eligibility.
For platelets or plasma, name the donation type when asking. Do not assume that changing collection type avoids a medication restriction. Memorial Sloan Kettering's blood-and-platelet list also identifies finasteride and dutasteride deferrals. MSK medication guidance.
Ask the service to confirm the earliest eligible date and any other conditions. If you already donated and later realized you omitted a medication, contact that service promptly with the donation details.
Treatment decisions deserve their own conversation. Our finasteride-to-dutasteride guide covers switching questions, while the topical-versus-oral finasteride guide explains why evidence depends on formulation. Neither replaces the donation service's screening decision.
Powered by BTST